Shire enters new year with new non-executive director
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.
Pharmaceuticals, Biotechnology and Life Sciences
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.
Analytical company Eurofins Scientific has broadened its testing facilities in Spain, as it is about to buy a Spanish pharmaceutical company Villapharma Research SL.
France’s Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.
A drug distributor owned by Cardinal Health Inc has agreed to pay $10 million to resolve claims that it failed to alert the U.S. Drug Enforcement Administration to suspicious orders of addictive painkillers by New York-area pharmacies.
Israeil’s largest drugmaker Teva Pharmaceuticals Industries has settled with the United States government over international bribery of government officials in…
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.
Xbrane Biopharma has named Anders P. Wiklund as strategic advisor. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB.
Ablynx has received a notification of shareholdings from FMR LLC, according to which its stake in Ablynx has slightly increased.
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…